124 related articles for article (PubMed ID: 2066966)
1. Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.
Repine JT; Himmelsbach RJ; Hodges JC; Kaltenbronn JS; Sircar I; Skeean RW; Brennan ST; Hurley TR; Lunney E; Humblet CC
J Med Chem; 1991 Jul; 34(7):1935-43. PubMed ID: 2066966
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.
Patt WC; Hamilton HW; Taylor MD; Ryan MJ; Taylor DG; Connolly CJ; Doherty AM; Klutchko SR; Sircar I; Steinbaugh BA
J Med Chem; 1992 Jul; 35(14):2562-72. PubMed ID: 1635057
[TBL] [Abstract][Full Text] [Related]
3. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.
Luly JR; BaMaung N; Soderquist J; Fung AK; Stein H; Kleinert HD; Marcotte PA; Egan DA; Bopp B; Merits I
J Med Chem; 1988 Dec; 31(12):2264-76. PubMed ID: 3143009
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.
Doherty AM; Sircar I; Kornberg BE; Quin J; Winters RT; Kaltenbronn JS; Taylor MD; Batley BL; Rapundalo SR; Ryan MJ
J Med Chem; 1992 Jan; 35(1):2-14. PubMed ID: 1732531
[TBL] [Abstract][Full Text] [Related]
5. Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.
Raddatz P; Minck KO; Rippmann F; Schmitges CJ
J Med Chem; 1994 Feb; 37(4):486-97. PubMed ID: 8120867
[TBL] [Abstract][Full Text] [Related]
6. Renin inhibitors containing alpha-heteroatom amino acids as P2 residues.
Repine JT; Kaltenbronn JS; Doherty AM; Hamby JM; Himmelsbach RJ; Kornberg BE; Taylor MD; Lunney EA; Humblet C; Rapundalo ST
J Med Chem; 1992 Mar; 35(6):1032-42. PubMed ID: 1552498
[TBL] [Abstract][Full Text] [Related]
7. Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Umeyama H; Ishida T; Kiso Y
J Med Chem; 1990 Oct; 33(10):2707-14. PubMed ID: 2120440
[TBL] [Abstract][Full Text] [Related]
8. Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'.
Raddatz P; Jonczyk A; Minck KO; Rippmann F; Schittenhelm C; Schmitges CJ
J Med Chem; 1992 Sep; 35(19):3525-36. PubMed ID: 1404233
[TBL] [Abstract][Full Text] [Related]
9. Novel renin inhibitors containing (2S,3S,5S)-2-amino-1-cyclohexyl-6-methyl-3,5-heptanediol fragment as a transition-state mimic at the P1-P1' cleavage site.
Yamada Y; Ando K; Ikemoto Y; Tada H; Shirakawa E; Inagaki E; Shibata S; Nakamura I; Hayashi Y; Ikegami K; Uchida I
Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1631-41. PubMed ID: 9353891
[TBL] [Abstract][Full Text] [Related]
10. Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
Ryan MJ; Hicks GW; Batley BL; Rapundalo ST; Patt WC; Taylor DG; Keiser JA
J Pharmacol Exp Ther; 1994 Jan; 268(1):372-9. PubMed ID: 8301578
[TBL] [Abstract][Full Text] [Related]
11. Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.
Rao CM; Scarborough PE; Kay J; Batley B; Rapundalo S; Klutchko S; Taylor MD; Lunney EA; Humblet CC; Dunn BM
J Med Chem; 1993 Sep; 36(18):2614-20. PubMed ID: 8410973
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of human renin that contain novel replacements at the P2 site.
Doherty AM; Kaltenbronn JS; Hudspeth JP; Repine JT; Roark WH; Sircar I; Tinney FJ; Connolly CJ; Hodges JC; Taylor MD
J Med Chem; 1991 Apr; 34(4):1258-71. PubMed ID: 1901910
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of three different potent renin inhibitors in primates.
Clozel JP; Fischli W
Hypertension; 1993 Jul; 22(1):9-17. PubMed ID: 8319997
[TBL] [Abstract][Full Text] [Related]
14. Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
Williams PD; Perlow DS; Payne LS; Holloway MK; Siegl PK; Schorn TW; Lynch RJ; Doyle JJ; Strouse JF; Vlasuk GP
J Med Chem; 1991 Mar; 34(3):887-900. PubMed ID: 2002469
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
Shibasaki M; Asano M; Fukunaga Y; Usui T; Ichihara M; Murakami Y; Nakano K; Fujikura T
Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of novel imidazole alcohol inhibitors of primate renin.
DeForrest JM; Waldron TL; Oehl RS; Scalese RJ; Free CA; Weller HN; Ryono DE
J Hypertens Suppl; 1989 Apr; 7(2):S15-9. PubMed ID: 2666607
[TBL] [Abstract][Full Text] [Related]
17. Renin inhibitors. III. Synthesis and structure-activity relationships of transition-state inhibitors containing dihydroxyethylene isostere at the P1-P1 site.
Atsuumi S; Funabashi H; Nakano M; Koike Y; Tanaka S; Harada J; Matsuyama K; Ikenaga T; Morishima H
Chem Pharm Bull (Tokyo); 1994 Feb; 42(2):306-13. PubMed ID: 8149456
[TBL] [Abstract][Full Text] [Related]
18. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative].
Muneta S
Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401
[TBL] [Abstract][Full Text] [Related]
19. An orally active renin inhibitor: cyclohexylnorstatine-containing dipeptide (KRI-1314).
Miyazaki M; Etoh Y; Iizuka K; Toda N
J Hypertens Suppl; 1989 Apr; 7(2):S25-7. PubMed ID: 2666609
[TBL] [Abstract][Full Text] [Related]
20. Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.
Dellaria JF; Maki RG; Bopp BA; Cohen J; Kleinert HD; Luly JR; Merits I; Plattner JJ; Stein HH
J Med Chem; 1987 Nov; 30(11):2137-44. PubMed ID: 3118024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
